Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context
Authors
Keywords
-
Journal
JOURNAL OF MEDICAL ECONOMICS
Volume 20, Issue 6, Pages 555-564
Publisher
Informa UK Limited
Online
2017-01-18
DOI
10.1080/13696998.2017.1284078
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial
- (2016) Marc S. Sabatine et al. AMERICAN HEART JOURNAL
- Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia
- (2016) Ioanna Gouni-Berthold et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States
- (2016) Shravanthi R. Gandra et al. CLINICAL CARDIOLOGY
- 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
- (2016) Alberico L. Catapano et al. EUROPEAN HEART JOURNAL
- Transatlantic Editorial: a comparison between European and North American guidelines on myocardial revascularization
- (2016) Philippe Kolh et al. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
- Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease
- (2016) Dhruv S. Kazi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses
- (2016) Gillian D. Sanders et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance
- (2016) Steven E. Nissen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality
- (2016) Rishi K. Wadhera et al. Journal of Clinical Lipidology
- A Retrospective Study to Examine Healthcare Costs Related to Cardiovascular Events in Individuals with Hyperlipidemia
- (2015) Henry J. Henk et al. ADVANCES IN THERAPY
- Effects of Evolocumab on Vitamin E and Steroid Hormone LevelsNovelty and Significance
- (2015) Dirk J. Blom et al. CIRCULATION RESEARCH
- Burden of First and Recurrent Cardiovascular Events Among Patients With Hyperlipidemia
- (2015) Rajeshwari S. Punekar et al. CLINICAL CARDIOLOGY
- Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective
- (2015) Tomas Jernberg et al. EUROPEAN HEART JOURNAL
- High-Risk Atherosclerotic Cardiovascular Disease in a Real-World Employed Japanese Population: Prevalence, Cardiovascular Event Rates, and Costs
- (2015) Keith L Davis et al. Journal of Atherosclerosis and Thrombosis
- PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
- (2015) Frederick J Raal et al. LANCET
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
- (2015) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Term Economic Burden Associated With Cardiovascular Events Among High-Risk Patients With Hyperlipidemia
- (2015) K.M. Fox et al. VALUE IN HEALTH
- ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance Measures
- (2014) Jeffrey L. Anderson et al. CIRCULATION
- Effects of Evolocumab (AMG 145), a Monoclonal Antibody to PCSK9, in Hypercholesterolemic, Statin-Treated Japanese Patients at High Cardiovascular Risk
- (2014) Atsushi Hirayama et al. CIRCULATION JOURNAL
- Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia
- (2014) Jennifer G. Robinson et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Anti-PCSK9 Monotherapy for Hypercholesterolemia
- (2014) Michael J. Koren et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold
- (2014) Peter J. Neumann et al. NEW ENGLAND JOURNAL OF MEDICINE
- 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
- (2013) Neil J. Stone et al. CIRCULATION
- 1-Year results from OSLER trial of anti-PCSK9 monoclonal antibody evolocumab
- (2013) Bryony M. Mearns Nature Reviews Cardiology
- Our time: a call to save preventable death from cardiovascular disease (heart disease and stroke)
- (2012) et al. EUROPEAN HEART JOURNAL
- Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients
- (2012) David Sullivan et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Health Care for Older Persons in England and the United States: A Contrast of Systems and Values
- (2011) Michael Gusmano et al. JOURNAL OF HEALTH POLITICS POLICY AND LAW
- Meta-Analysis of Randomized Controlled Trials of Statins Versus Placebo in Patients With Heart Failure
- (2009) Michael J. Lipinski et al. AMERICAN JOURNAL OF CARDIOLOGY
- Harmonizing the Metabolic Syndrome
- (2009) K.G.M.M. Alberti et al. CIRCULATION
- ASHP Guidelines on the Pharmacy and Therapeutics Committee and the Formulary System
- (2008) Linda S. Tyler et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search